Nature Reviews Drug Discovery

Nature Reviews Drug Discovery, Published online: 12 August 2026; doi:10.1038/d41573-026-00136-z Oncolytic virus nabs FDA approval

Nature Reviews Drug Discovery, Published online: 10 August 2026; doi:10.1038/d41573-026-00135-0 As Takeda’s oveporexton (Orzeyful) becomes a first-in-class treatment for narcolepsy type 1, industry eyes broader indications for orexin receptor agonists.

Nature Reviews Drug Discovery, Published online: 07 August 2026; doi:10.1038/s41573-026-01496-2 Applications of artificial intelligence (AI) in drug discovery have attracted high interest in recent years, but evidence for clinically relevant impact so far is limited. This Perspective discusses potential reasons, including an insufficient focus on clinical translation during model development and …

Nature Reviews Drug Discovery, Published online: 06 August 2026; doi:10.1038/d41573-026-00134-1 Lilly spends US$2.8 billion on psychedelic drugs for mental health

Nature Reviews Drug Discovery, Published online: 06 August 2026; doi:10.1038/d41573-026-00133-2 First dual BAFF and APRIL inhibitor nabs FDA approval

Nature Reviews Drug Discovery, Published online: 05 August 2026; doi:10.1038/d41573-026-00132-3 Expanding the molecular glue target space

Nature Reviews Drug Discovery, Published online: 04 August 2026; doi:10.1038/d41573-026-00127-0 Targeting tumour-associated macrophages

Nature Reviews Drug Discovery, Published online: 04 August 2026; doi:10.1038/d41573-026-00126-1 Phage therapy for Crohn’s disease

Nature Reviews Drug Discovery, Published online: 04 August 2026; doi:10.1038/d41573-026-00129-y Designing small-molecule binding proteins

Nature Reviews Drug Discovery, Published online: 04 August 2026; doi:10.1038/d41573-026-00128-z Gene megacluster produces synergistic antibiotics

Nature Reviews Drug Discovery, Published online: 04 August 2026; doi:10.1038/d41573-026-00131-4 Optimizing translation of therapeutic mRNAs

Nature Reviews Drug Discovery, Published online: 30 July 2026; doi:10.1038/d41573-026-00123-4 Oral macrocyclic PCSK9 inhibitor secures FDA approval

Nature Reviews Drug Discovery, Published online: 30 July 2026; doi:10.1038/d41573-026-00124-3 Small molecules stop β-arrestins

Nature Reviews Drug Discovery, Published online: 28 July 2026; doi:10.1038/d41573-026-00122-5 Prostaglandin E2 drives cancer-associated cachexia

Nature Reviews Drug Discovery, Published online: 24 July 2026; doi:10.1038/s41573-026-01495-3 T follicular helper (TFH) cells support B cell function to promote long-lasting antibody responses but are implicated in many diseases and undergo age-related changes. This Review explores emerging therapeutic strategies to modulate TFH cells, including boosting their function for vaccination and infecti…

Nature Reviews Drug Discovery, Published online: 20 July 2026; doi:10.1038/s41573-026-01482-8 The changing face of UK academic drug screening in the past decade

Nature Reviews Drug Discovery, Published online: 16 July 2026; doi:10.1038/d41573-026-00121-6 Efforts intensify to ferry large-molecule medicines into the brain, following the first FDA approval of an engineered biologic that overcomes delivery hurdles.

Nature Reviews Drug Discovery, Published online: 13 July 2026; doi:10.1038/s41573-026-01481-9 Simulation-guided clinical trial design can enable identification of the optimal design to bring safe and effective therapies to patients as efficiently as possible, and it is particularly useful when exploring innovative strategies such as adaptive designs and master protocols. This Perspective discusse…

Nature Reviews Drug Discovery, Published online: 10 July 2026; doi:10.1038/d41573-026-00120-7 FDA new drug approvals in Q2 2026

Nature Reviews Drug Discovery, Published online: 09 July 2026; doi:10.1038/s41573-026-01484-6 Addressing challenges in treating rare tumours: the strategy of China’s National Cancer Center